Last reviewed · How we verify
IL-3
IL-3, marketed by the National Cancer Institute (NCI), holds a unique position in its therapeutic class. The drug's key composition patent is set to expire in 2028, providing a significant period of market exclusivity. However, the lack of revenue data and primary trial results highlights a potential risk in assessing its commercial and clinical performance.
At a glance
| Generic name | IL-3 |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant (PHASE1)
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (PHASE1, PHASE2)
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) (PHASE2)
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (PHASE2)
- Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE1, PHASE2)
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (PHASE1)
- Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-3 CI brief — competitive landscape report
- IL-3 updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI